Is HPV vaccination in pregnancy safe?

References

• al. Fe. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International journal of Cancer 2015; 136(5):E359-86. http://dx.doi.org/10.1002/ijc.29210; Epub 2014 Oct 9.
   Google Scholar
• de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048-56; PMID:20952254; http://dx.doi.org/10.1016/S1470-2045(10)70230-8
   PubMed Web of Science ®Google Scholar
• Poland GA, Jacobson RM, Koutsky LA, Tamms GM, Railkar R, Smith JF, Bryan JT, Cavanaugh PF, Jr., Jansen KU, Barr E. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Mayo Clin Proc 2005; 80:601-10; PMID:15887427; http://dx.doi.org/10.4065/80.5.601
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED, Jr., Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711-23; PMID:25693011; http://dx.doi.org/10.1056/NEJMoa1405044
   PubMed Web of Science ®Google Scholar
• Human papillomavirus vaccines: WHO position paper, October 2014. Releve epidemiologique hebdomadaire / Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations 2014; 89(43): 465-91.
   Google Scholar
• Liu G, Kong L, Du P. HPV vaccine completion and dose adherence among commercially insured females aged 9 through 26 years in the US. Papillomavirus Res 2016; 2:1-8; PMID:26623444; http://dx.doi.org/10.1016/j.pvr.2015.10.001
   PubMedGoogle Scholar
• Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol 2015; 16:775-86; PMID:26071347; http://dx.doi.org/10.1016/S1470-2045(15)00047-9
   PubMed Web of Science ®Google Scholar
• Division PHWHP. Vaccine uptake in Children in Wales, April to June 2012: COVER report 103, August 201. Cardiff, Public Health Wales. 2012.
   Google Scholar
• Widgren K, Simonsen J, Valentiner-Branth P, Molbak K. Uptake of the human papillomavirus-vaccination within the free-of-charge childhood vaccination programme in Denmark. Vaccine 2011; 29:9663-7; PMID:22015392; http://dx.doi.org/10.1016/j.vaccine.2011.10.021
   PubMed Web of Science ®Google Scholar
• 2013. SSIAJ. EPI-NEWS HPV-vaccination - coverage 2012. Available from: http://www.ssidk/English/News/EPI-NEWS/2013/No%2020%20-%202013aspx
   Google Scholar
• Barbaro B, Brotherton JM. Assessing HPV vaccine coverage in Australia by geography and socioeconomic status: are we protecting those most at risk? Aust N Z J Public Health 2014; 38:419-23; PMID:24962721; http://dx.doi.org/10.1111/1753-6405.12218
   PubMed Web of Science ®Google Scholar
• Human Papillomavirus Vaccination Coverage Among Adolescent Girls, 2007-2012, and Postlicensure Vaccine Safety Monitoring, 2006-2013, United States. 2015
   Google Scholar
• http://www.cdc.gov/vaccines/pubs/preg-guide.htm - hpv
   Google Scholar
• Human Papillomavirus Vaccination - ACOG. 2015.
   Google Scholar
• Singh S, Sedgh G, Hussain R. Unintended Pregnancy: Worldwide Levels, Trends, and Outcomes. Stud Fam Plann 2010; 41:241-50; PMID:21465725; http://dx.doi.org/10.1111/j.1728-4465.2010.00250.x
   PubMed Web of Science ®Google Scholar
• Wacholder S, Chen BE, Wilcox A, Macones G, Gonzalez P, Befano B, Hildesheim A, Rodriguez AC, Solomon D, Herrero R, et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ 2010; 340:c712; PMID:20197322; http://dx.doi.org/10.1136/bmj.c712
   PubMed Web of Science ®Google Scholar
• Panagiotou OA, Befano BL, Gonzalez P, Rodriguez AC, Herrero R, Schiller JT, Kreimer AR, Schiffman M, Hildesheim A, Wilcox AJ, et al. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. BMJ 2015; 351:h4358; PMID:26346155; http://dx.doi.org/10.1136/bmj.h4358
   PubMed Web of Science ®Google Scholar
• Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, Saah A, Marino D, Ryan D, Radley D, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009; 114:1179-88; PMID:19935017; http://dx.doi.org/10.1097/AOG.0b013e3181c2ca21
   PubMed Web of Science ®Google Scholar
• Dana A, Buchanan KM, Goss MA, Seminack MM, Shields KE, Korn S, Cunningham ML, Haupt RM. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009; 114:1170-8; PMID:19935016; http://dx.doi.org/10.1097/AOG.0b013e3181c2a122
   PubMed Web of Science ®Google Scholar
• Angelo MG, David MP, Zima J, Baril L, Dubin G, Arellano F, Struyf F. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf 2014; 23:466-79; PMID:24644063; http://dx.doi.org/10.1002/pds.3554
   PubMed Web of Science ®Google Scholar
• Scheller NM, Pasternak B, Svanstrom H, Hviid A. Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism. JAMA 2014; 312:187-8; http://dx.doi.org/10.1001/jama.2014.2198
   PubMed Web of Science ®Google Scholar
• Scheller NM, Svanstrom H, Pasternak B, Arnheim-Dahlstrom L, Sundstrom K, Fink K, Hviid A. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA 2015; 313:54-61; http://dx.doi.org/10.1001/jama.2014.16946
   PubMed Web of Science ®Google Scholar
• Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, Sparen P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013; 347:f5906; PMID:24108159.
   PubMed Web of Science ®Google Scholar
• Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, Sings HL, Perez G, Haupt RM, Saah AJ, et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J 2015; 34:983-91; PMID:26107345; http://dx.doi.org/10.1097/INF.0000000000000793
   PubMed Web of Science ®Google Scholar
• Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009; 5:332-40; PMID:19221517; http://dx.doi.org/10.4161/hv.5.5.7211
   PubMed Web of Science ®Google Scholar
• European Medicines Agency - News and Events - Review concludes evidence does not support that HPV vaccines cause CRPS or POTS. 2015
   Google Scholar
• Toh ZQ, Licciardi PV, Fong J, Garland SM, Tabrizi SN, Russell FM, Mulholland EK. Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art. Vaccine 2015; 33:5042-50; PMID:26271829; http://dx.doi.org/10.1016/j.vaccine.2015.07.102
   PubMed Web of Science ®Google Scholar